Go back

France begins clinical trial death inquiry

Image: Jason [CC BY 2.0], via Flickr

The French authorities have begun an investigation into the death of a phase I clinical trial participant and the hospitalisation of five more.

/* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin-top:0cm; mso-para-margin-right:0cm; mso-para-margin-bottom:10.0pt; mso-para-margin-left:0cm; line-height:115%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-fareast-language:EN-US;} The clinical trial was being carried out at a facility in Rennes run by Biotrial, a contract research organisation. Biotrial was testing the drug BIA 10-2474, made by Bial, a company based in Portugal. The drug was intended as a treatment for anxiety, chronic pain and movement disorders associated with Parkinson’s disease.

On 15 January, France’s ministry for health issued a brief statement saying that six of the participants in the trial had been hospitalised, including one who had been left brain dead. That patient—who was subsequently named by the French press as Guillaume Molinet, a 49-year-old man from the village of Guilliers near Rennes—died on 17 January.

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.